Cellectar Biosciences Inc (NASDAQ: CLRB) is having an incredibly strong start to the trading session this morning, and for good reason. The company provided an update with regard to its lead candidate, CLR 131. Of course, the update excited investors, pushing the stock up. Today, we’ll talk about: The CLR 131 update; what we’re seeing … Read more
Cellectar Biosciences Inc (NASDAQ: CLRB) is having an incredibly strong start to the trading session this morning, and for good reason. The company announced that it has been granted Fast Track Designation by the FDA, exciting investors and sending the stock for the top. Today, we’ll talk about: The Fast Track Designation; what we’re seeing … Read more
The oncology space is one that is undergoing a rapid evolution. With nearly 600,000 deaths per year, cancer is the second leading cause of death in the United States, and it has the attention of world class researchers internationally. This innovation in medicine has led to more treatment options than ever before, but it’s not … Read more
Cellectar Biosciences Inc (NASDAQ: CLRB) is flying early on in the trading session this morning, and for good reason. The company announced news with regard to an Import Alert exemption, exciting investors and sending the stock screaming for the top. Today, we’ll talk about: The granted exception; what we’re seeing from CLRB stock as a … Read more
Cellectar Biosciences Inc (NASDAQ: CLRB) is a stock that I’ve been hammering home for the past several sessions as I saw an opportunity on the horizons. Well, for those that get in within the next few minutes, that opportunity is going to get very real, very quickly. As I pointed out in previous posts, we’ve … Read more
Synthetic Biologics Inc (NYSEAMERICAN: SYN) has seen incredible gains in the market as of late. While the company has released no recent news, there is a reason for the gains. Unfortunately however, I believe that we’ve reached the end of the line here. Nonetheless, there is another opportunity out there that may make SYN gains … Read more
Cellectar Biosciences Inc (NASDAQ: CLRB) is creating an interesting opportunity. In the week or two ahead, there are a couple of events that are likely to take place that I believe will keep the stock on the uptrend. First, updated data from CLR 131 is expected by the end of the month. If this data is positive, … Read more
Cellectar Biosciences Inc (NASDAQ: CLRB) has had an incredible run in the market over the past several trading sessions, capping of the gains with yesterday’s close over 24% higher than the close on Tuesday. Nonetheless, if you think you’ve missed the boat, think again. Today, we’ll talk about: Why the stock is running and why … Read more
Cellectar Biosciences Inc (NASDAQ: CLRB) is having an incredibly strong start to the trading session this morning, flying on high volume. The gains are coming for good reason. News broke this morning surrounding a designation the company received from the FDA for CLR-131. Of course, the news was positive, leading to excitement among investors and … Read more
Cellectar Biosciences Inc (NASDAQ: CLRB) was having a pretty flat day in the market early on today. However, minutes ago, the company announced that its flagship candidate has been granted Orphan Drug Designation from the United States Food and Drug Administration (FDA). Today, we’ll talk about: The Orphan Drug Designation; what we’re seeing from the … Read more